Ovid Therapeutics Inc.
GABOXADOL FOR THERAPEUTIC TREATMENT OF 1p36 DELETION SYNDROME
Last updated:
Abstract:
Methods and pharmaceutical compositions containing gaboxadol or a pharmaceutically acceptable salt thereof for treating 1p36 deletion syndrome are provided.
Status:
Application
Type:
Utility
Filling date:
18 Dec 2020
Issue date:
24 Jun 2021